The following slide deck was published by Hansa Biopharma AB (publ) in conjunction with their 2022 Q4 earnings call.
For further details see:
Hansa Biopharma AB (publ) 2022 Q4 - Results - Earnings Call Presentationhome / stock / hnsbf / hnsbf news
The following slide deck was published by Hansa Biopharma AB (publ) in conjunction with their 2022 Q4 earnings call.
For further details see:
Hansa Biopharma AB (publ) 2022 Q4 - Results - Earnings Call PresentationMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Hansa Biopharma AB Company Name:
HNSBF Stock Symbol:
Market:
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting PR Newswire LUND , Sweden , May 21, 2024 /PRNewswire/ --. Hansa Biopharma, "Hansa" (NASDAQ: HNSA) (STOCKHOLM: HNSA), today announced data featuring imlifidase will be present...
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation PR Newswire Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared ...
Hansa Biopharma interim report January-March 2023 PR Newswire Positive reimbursement decision in Spain expands market access to include the five largest European markets Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed HNSA-...